Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Fedoriw et al. show that the type I protein arginine methyltransferases (PRMT) inhibitor GSK3368715 has strong anti-cancer activity and synergizes with PRMT5 inhibition. MTAP deficiency causes accumulation of an endogenous PRMT5 inhibitor, suggesting MTAP status as a predictive biomarker for GSK3368715.

from Cancer Cell https://ift.tt/2NhFsEY